Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Kexun Zhou, Shuo Li, Yi Zhao, Ke Cheng
Abstract
Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.
Topics & Concepts
MedicineLung cancerTumor microenvironmentDrug resistanceDiseaseCancerImmune systemImmune checkpointPopulationImmunotherapyImmunologyCancer researchOncologyInternal medicineBiologyMicrobiologyEnvironmental healthCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies